Healthcare

SB 45 repeals Utah's 2019 Kratom Consumer Protection Act and classifies alkaloids found in kratom as Schedule I controlled substances under state law. This change directly affects kratom users and businesses in Utah, removing previous regulatory protections and making kratom possession or sale illegal under state law. The bill amends Utah's controlled substances code to include kratom alkaloids in Schedule I, which prohibits use due to no accepted medical purpose and high abuse potential. This policy shift reverses prior regulations that allowed regulated sale and use of kratom products.

SB 174 allows health care providers, institutions, and payers in Utah to refuse participation in certain medical services (like pregnancy termination disposal) based on religious, moral, or ethical beliefs. It requires providers who refuse such services to notify their institution and prohibits retaliation, discrimination, or adverse actions against them for exercising this right. The bill also shields these individuals from civil, criminal, or administrative liability and mandates health care payers to disclose services they won’t cover due to conscience objections. It defines key terms like "conscience" and "adverse action" to clarify protections and enforcement mechanisms. The bill makes no changes to funding and applies to all covered health care entities under Utah law.

HB 527 amends Utah's pharmacy pricing rules to require pharmacy benefit managers to base reimbursement rates only on drugs rated "A" or "B" in the FDA's Orange Book (or similar ratings) that are not obsolete and generally available in the state. It clarifies key terms like "maximum allowable cost" and "rebate," and grants the Insurance Department authority to create implementing rules. This directly affects pharmacies, pharmacy benefit managers, and insurers by changing how drug reimbursement rates are calculated. The bill does not appropriate funds or create new taxes.

HB 174 prohibits health care providers in Utah from administering cross-sex hormones or puberty blockers to minors after January 28, 2027, unless the minor was diagnosed with gender dysphoria before January 28, 2023. The bill amends Utah Code Section 58-1-603.1 to establish this ban, directly affecting minors seeking these treatments who do not meet the pre-2023 diagnosis requirement. It repeals a prior requirement for medical evidence reviews (Section 26B-1-239) and takes effect on May 6, 2026. The law applies to all minors under Utah's definition, with violations classified as unprofessional conduct for providers.